Mochida's Epadel (ethyl icosapentate) has failed to show benefits over placebo in the treatment of non-alcoholic steatohepatitis (NASH), marking a setback for the fish oil-derived prescription product just as it is switching to over-the-counter sale in Japan for hyperlipidemia.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?